A new era for Waldenstrom macroglobulinemia: MYD88 L265P

Blood

Volumn 121, Issue 22, 2013, Pages 4434-4436

  Treon, Steven P ^a,b   Hunter, Zachary R ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; MYD88 PROTEIN, HUMAN;

CELL EXPANSION; CHRONIC LYMPHATIC LEUKEMIA; DIFFUSE LARGE B CELL LYMPHOMA; HUMAN; MARGINAL ZONE LYMPHOMA; MYELOMA; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SOMATIC MUTATION; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; FEMALE; GENETICS; MALE; POINT MUTATION;

FEMALE; HUMANS; MALE; MYELOID DIFFERENTIATION FACTOR 88; POINT MUTATION; WALDENSTROM MACROGLOBULINEMIA;

MLCS; MLOWN;

EID: 84880835216     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-494849     Document Type: Note

References (10)

1. Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom’s macroglogulinemia. Blood. 2013;121(22):4504-4511.
2. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9):826-833.
3. Gachard N, Parrens M, Soubeyran I, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia. 2013;27(1):183-189.
4. Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051-2058.
5. Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med. 2012;367(23): 2255-2256, author reply 2256-2257.
6. Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13): 2522-2528.
7. Jiménez C, Sebastián E, Del Carmen Chillón M, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia [published online ahead of print March 22, 2013]. Leukemia.
8. Ansell SM, Secreto FJ, Manske M, et al. MYD88 pathway activation in lymphoplasmacytic lymphoma drives tumor cell growth and cytokine expression [abstract]. Blood. 2012;120(21):2699. Abstract 2699.
9. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115-119.
10. Yang G, Xu L, Zhou Y, et al. Participation of BTK in MYD88 signaling in malignant cells expressing the L265P mutation in Waldenstrom’s macroglobulinemia, and effect on tumor cells with BTK-inhibitor PCI-32765 in combination with MYD88 pathway inhibitors [abstract]. J Clin Oncol. 2012;30(15, suppl):8106. Abstract 8106.